Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan

Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan

Background. To determine the maximum tolerable infusion rate of rituximab, and investigate the safety and feasibility of rapid infusion of rituximab for patients with CD20 positive B-cell lymphomas (CD20+NHL). Patients and Methods. 18 patients with CD20+NHL were registered. This study had six cohor...

Full description

Bibliographic Details
Main Authors: Yokoyama, Masahiro, Terui, Yasuhito, Takeuchi, Kengo, Nara, Eriko, Nakano, Kenji, Ueda, Kyoko, Nishimura, Noriko, Mishima, Yuko, Sakajiri, Sakura, Tsuyama, Naoko, Ozawa, Keiya, Hatake, Kiyohiko
Format: Online
Language:English
Published: Hindawi Publishing Corporation 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649348/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649348/

Similar Items